| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 1183.6 | 938.4 | 979.9 |
| Other income | 72.8 | 43.8 | 33.6 |
| Total income | 1256.3 | 982.2 | 1013.5 |
| Profit before exceptional items & tax | 459.3 | 322.4 | 351.4 |
| Exceptional items | 0.0 | 0.0 | 2.6 |
| Profit before tax | 459.3 | 322.4 | 354.0 |
| Net profit | 335.9 | 237.2 | 257.5 |
| Operating margin | 36.6% | 32.8% | 34.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +30.40% |
|---|---|
| Net profit, quarter on quarter | +41.60% |
| Revenue, year on year | +20.80% |
| Operating profit, year on year | +21.60% |
| Operating profit, quarter on quarter | +38.70% |
BSE results filing, NSE: GLAXO. Figures extracted from the filing.
GlaxoSmithKline Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,575.10
- Market cap
- ₹43,624 Cr
- Revenue (annual)
- ₹3,822 Cr
- Net profit (annual)
- ₹1,036 Cr
- P/E (TTM)
- 40.8×Sector 47.2×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 4.75%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from GlaxoSmithKline Pharmaceuticals Ltd
All →GlaxoSmithKline Pharmaceuticals Management Change
GlaxoSmithKline Pharmaceuticals appointed Sandeep Seth as Head - Ethics & Compliance, effective 3 November 2026. He brings over 20 years of compliance and governance experience.
GlaxoSmithKline Pharmaceuticals Other Announcement
GSK Pharmaceuticals appointed M/s. Walker Chandiok & Co. LLP as Statutory Auditor, effective 1 April 2027 for a 60-month term. The appointment was approved at the board meeting held on 3 November 2026.
- Execution
- 1 April 2027 for 60 months
GlaxoSmithKline Pharmaceuticals Results Update
GSK Pharmaceuticals reported Q2 FY27 media release showing revenue of INR 1180 crore (up 21%) and PAT of INR 335 crore (up 31%). The release also announces the upcoming BLENREP launch in India.
GlaxoSmithKline Pharmaceuticals Board Meeting Date
GlaxoSmithKline Pharmaceuticals Limited will hold a board meeting on 3rd November 2026 to consider and approve its unaudited financial results for the quarter ended 30th September 2026.
GlaxoSmithKline Pharmaceuticals Other Announcement
GlaxoSmithKline Pharmaceuticals Ltd has filed its quarterly shareholding pattern for the quarter ended September 30, 2026, as required by SEBI listing regulations.
GlaxoSmithKline Pharmaceuticals Annual General Meeting
GSK Pharma's postal ballot approved Ms. Natland as NED and Mr. Akshikar's MD re-appointment. Both resolutions cleared with over 99% shareholder support.